Tenaya Therapeutics Extends Cash Runway to Mid-2027, Focusing on Cardiac Gene Therapy

Tenaya Therapeutics, a biotechnology company, has extended its cash runway to mid-2027 through a US$60,000,000 capital raise. This allows the company to focus on advancing gene therapies for inherited heart diseases, particularly with its TN-201 and TN-401 cardiac gene therapy programs. Investors are now watching for clinical safety signals, data consistency, and regulatory feedback on pivotal trial design.